Products

Soralieva 200mg Tablet: Multi-Kinase Inhibition for Advanced Hepatic, Renal, and Thyroid Oncology Are you searching for a reliable Soralieva 200 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted multi-kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Soralieva 200mg? Universal SEO Page Title (Multi-City Targeted) Soralieva 200mg Tablet | Wholesale Sorafenib Exporter to London, Washington, Canberra, Johannesburg & Singapore—Ernest Oncology Soralieva 200mg Tablet: Multi-Kinase Inhibition for Advanced Hepatic, Renal, and Thyroid Oncology Are you searching for a reliable Soralieva 200 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted multi-kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Soralieva 200mg? Soralieva 200mg is an oral targeted therapy containing the active pharmaceutical ingredient Sorafenib. Manufactured by Allieva Pharma Pvt Ltd, this 200mg tablet is a potent multi-kinase inhibitor designed to treat various types of cancers by attacking both the cancer cells and the blood vessels that supply them. It represents a significant advancement in the non-surgical management of advanced solid tumors. 1. Therapeutic Indications Hepatocellular Carcinoma (HCC): Indicated for the treatment of patients with unresectable liver cancer. Advanced Renal Cell Carcinoma (RCC): Used for patients with advanced kidney cancer who have failed prior cytokine-based therapy or are unsuitable for it. Differentiated Thyroid Carcinoma (DTC): Specifically for locally advanced or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine. 2. Mechanism of Action: The Dual-Action Approach Anti-Proliferative Activity: It inhibits the Raf/MEK/ERK signaling pathway. By blocking these intracellular kinases, it directly prevents the division and growth of cancer cells. Anti-Angiogenic Activity: It targets cell surface tyrosine kinases, including VEGFR-2, VEGFR-3, and PDGFR-beta. This “starves“ the tumor by inhibiting the development of new blood vessels (angiogenesis) required for tumor survival and expansion. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is 400mg (two 200mg tablets) taken twice daily. Administration: For optimal absorption, Soralieva should be taken either 1 hour before or 2 hours after a meal (on an empty stomach). Consistency: Tablets must be swallowed whole with a glass of water. Do not crush or chew the tablets. Clinical Side Effects & Safety Monitoring Hand-Foot Skin Reaction (HFSR): Redness, pain, or swelling on the palms and soles is common; early management with topical creams is advised. Hypertension (High Blood Pressure): Blood pressure usually increases within the first few weeks; regular monitoring is essential. Gastrointestinal Health: Potential for diarrhea, fatigue, and weight loss. Cardiovascular Safety: Patients should be monitored for signs of myocardial ischemia or infarction. Dermatological Safety: Patients should report any new skin lesions or significant rashes immediately. Why Source Soralieva 200mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Soralieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for the USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Axilieva 5mg Tablet: Dual-Mechanism Tyrosine Kinase Inhibition for Advanced Renal Cell Carcinoma Are you searching for a reliable Axilieva 5 mg tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted anti-angiogenic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Axilieva 5mg? Axilieva 5mg is an oral targeted therapy containing the active pharmaceutical ingredient Axitinib. Manufactured by Allieva Pharma Pvt Ltd, this 5mg tablet is a potent second-generation tyrosine kinase inhibitor (TKI). It is specifically designed to treat advanced kidney cancer by inhibiting the signals that promote tumor growth and the development of supporting blood vessels. 1. Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Primarily indicated for patients with advanced kidney cancer after the failure of one prior systemic therapy (such as a previous TKI or cytokine treatment). Combination Protocols: Often utilized in advanced clinical settings in combination with immunotherapy agents to improve progression-free survival. Targeted Tumor Control: Effective in slowing the progression of malignant cells that have originated in the kidneys and potentially spread to other organs. 2. Mechanism of Action: Anti-Angiogenesis and Signal Interruption Inhibition of Angiogenesis: It selectively inhibits Vascular Endothelial Growth Factor Receptors (VEGFR-1, VEGFR-2, and VEGFR-3). This effectively “starves“ the tumor by blocking the formation of new blood vessels needed for oxygen and nutrient supply. Disruption of Growth Signaling: By targeting specific receptor tyrosine kinases, it interrupts the abnormal signaling pathways that drive uncontrolled cell proliferation and survival in cancer cells. High Potency: As a second-generation inhibitor, it is designed to be more potent than earlier TKIs, allowing for effective receptor blockade even at lower concentrations. 3. Administration and Dosage Management Standard Dosing: The typical starting dose is 5mg taken twice daily (approximately 12 hours apart). Administration: Can be taken with or without food. Tablets must be swallowed whole with a glass of water and should not be crushed or chewed. Dose Titration: Based on individual patient tolerance and blood pressure response, the dose may be adjusted (increased or decreased) under strict oncological supervision. Clinical Side Effects & Safety Monitoring Hypertension (High Blood Pressure): This is a very common side effect; blood pressure should be well-controlled before starting and monitored frequently during treatment. Gastrointestinal Health: Potential for diarrhea, nausea, and decreased appetite. Maintaining hydration is essential. Thyroid Function: Risk of hypothyroidism; routine monitoring of thyroid-stimulating hormone (TSH) levels is recommended. Bleeding and Wound Healing: Due to its anti-angiogenic nature, it may increase the risk of bleeding or impair wound healing; it is often discontinued before major surgeries. Hand-Foot Syndrome: Monitoring for redness or pain on the palms and soles. Why Source Axilieva 5mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Axilieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Hydlieva 500mg Capsule: Potent Antineoplastic Therapy for Hematologic and Solid Tumor Management Are you searching for a reliable Hydlieva 500mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced cytotoxic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Hydlieva 500mg? Hydlieva 500mg is an oral antineoplastic (anti-cancer) therapy containing the active pharmaceutical ingredient Hydroxyurea (also known as Hydroxycarbamide). Manufactured by Allieva Pharma Pvt Ltd, this 500mg capsule is a versatile antimetabolite used to treat a variety of proliferative disorders. It is a vital component in managing both malignant blood cancers and certain non-cancerous blood conditions. 1. Therapeutic Indications Chronic Myeloid Leukemia (CML): Specifically for resistant cases to help control the overproduction of white blood cells. Head and Neck Cancers: Used in combination with radiotherapy for locally advanced squamous cell carcinomas (excluding the lip). Sickle Cell Anemia: Indicated to reduce the frequency of painful crises and the need for blood transfusions in adult and pediatric patients. Polycythemia Vera & Essential Thrombocythemia: Used to manage excessive production of red blood cells and platelets, reducing the risk of blood clots and stroke. Cervical Cancer: Occasionally utilized as a radiosensitizer in comprehensive treatment protocols. 2. Mechanism of Action: Ribonucleotide Reductase Inhibition DNA Synthesis Inhibition: It acts as a potent inhibitor of the enzyme ribonucleotide reductase. This enzyme is essential for converting ribonucleotides into deoxyribonucleotides (the building blocks of DNA). S-Phase Specificity: By blocking DNA synthesis, Hydlieva prevents cancer cells from replicating their genetic material, halting them in the S-phase of the cell cycle. Fetal Hemoglobin Induction: In sickle cell disease, it increases the production of fetal hemoglobin (HbF), which prevents red blood cells from “sickling“ and improves oxygen transport. 3. Administration and Dosage Management Standard Dosing: The dose is highly individualized based on the patient's body weight, blood counts, and the specific condition being treated. Administration: Capsules should be swallowed whole. If the patient cannot swallow them, the contents may be dissolved in a glass of water and taken immediately. Safety Handling: As a cytotoxic agent, caregivers should wear disposable gloves when handling the capsules or powder to avoid direct skin contact. Clinical Side Effects & Safety Monitoring Bone Marrow Suppression: The most significant risk is a drop in white blood cells (leukopenia), platelets (thrombocytopenia), and red blood cells (anemia). Regular blood counts are mandatory. Cutaneous Toxicities: Potential for skin ulcers, darkening of the skin or nails, and in rare cases, secondary skin cancers (monitoring and sun protection are advised). Gastrointestinal Health: Nausea, vomiting, diarrhea, and mouth sores (stomatitis) are common side effects. Pulmonary Monitoring: Rare cases of interstitial lung disease or fibrosis have been reported; patients should report any new shortness of breath. Why Source Hydlieva 500mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Hydlieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

BICALIEVA 50mg Tablet: Targeted Non-Steroidal Anti-Androgen Therapy for Prostate Cancer Management Are you searching for a reliable BICALIEVA 500 mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted endocrine therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is BICALIEVA 50 mg? BICALIEVA 50 mg is an oral targeted therapy containing the active pharmaceutical ingredient Bicalutamide. Manufactured by Allieva Pharma Pvt Ltd, this 50mg tablet belongs to the class of medications known as Non-Steroidal Anti-Androgens. It is specifically designed to treat advanced prostate cancer by neutralizing the effects of male hormones (androgens) that stimulate the growth of malignant cells. 1. Therapeutic Indications Advanced Prostate Cancer: Used in combination therapy with a Luteinizing Hormone-Releasing Hormone (LHRH) analog (like Leuprolide or Goserelin). Metastatic Disease: Effective in managing Stage D2 metastatic carcinoma of the prostate. Hormone-Sensitive Prostate Cancer: Often utilized as part of a “Combined Androgen Blockade“ (CAB) to maximize treatment efficacy. Flaring Prevention: Administered at the start of LHRH agonist therapy to prevent the “testosterone flare“ that can temporarily worsen symptoms. 2. Mechanism of Action: Androgen Receptor Inhibition Receptor Blocking: It competitively binds to the cytosol androgen receptors in the target tissue (the prostate gland). Signal Interruption: By occupying these receptors, it prevents Dihydrotestosterone (DHT) and Testosterone from binding to the cancer cells. Tumor Suppression: Without the “fuel“ provided by androgens, the growth of prostate cancer cells is inhibited, and the tumor may shrink or stabilize. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is one 50mg tablet taken once daily. Administration: Can be taken with or without food. Tablets should be swallowed whole at the same time each day. Combination Timing: When used with an LHRH agonist, treatment with Bicalieva should be started at the same time as the injection to ensure maximum hormonal control. Clinical Side Effects & Safety Monitoring Hepatotoxicity: Rare but serious liver injury can occur; Liver Function Tests (LFTs) should be performed regularly. Gynecomastia: Breast tenderness or enlargement is a common side effect due to hormonal shifts. Vasomotor Symptoms: Potential for hot flashes and generalized weakness or fatigue. Glucose Tolerance: Patients with diabetes should monitor blood sugar levels, as anti-androgens can affect insulin sensitivity. Why Source BICALIEVA 50mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s BICALIEVA with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Nindalieva 150mg Capsule: Advanced Tyrosine Kinase Inhibition for Pulmonary and Oncology Management Are you searching for a reliable Nindalieva 150mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced antifibrotic and antineoplastic therapies. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Nindalieva 150mg? Nindalieva 150mg is an oral targeted therapy containing the active pharmaceutical ingredient Nintedanib. Manufactured by Allieva Pharma Pvt Ltd, this 150mg capsule is a potent small-molecule tyrosine kinase inhibitor (TKI). It is specifically engineered to block pathways involved in the progression of pulmonary fibrosis and the growth of specific types of lung tumors, making it a cornerstone in respiratory and oncology care. 1. Therapeutic Indications Idiopathic Pulmonary Fibrosis (IPF): Used to slow the decline in lung function in patients with chronic, progressive scarring of lung tissue. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Indicated to slow the rate of decline in pulmonary function in patients with connective tissue disease-related lung involvement. Progressive Fibrosing Interstitial Lung Diseases (ILDs): For patients with a chronic fibrosing phenotype that continues to worsen despite treatment. Non-Small Cell Lung Cancer (NSCLC): In specific global regions, it is used in combination with Docetaxel for the treatment of advanced adenocarcinoma after first-line chemotherapy. 2. Mechanism of Action: Triple Kinase Inhibition Inhibition of Pro-Fibrotic Pathways: It targets Platelet-Derived Growth Factor Receptors (PDGFR), Fibroblast Growth Factor Receptors (FGFR), and Vascular Endothelial Growth Factor Receptors (VEGFR). Blocking Fibroblast Proliferation: By inhibiting these signaling pathways, it prevents the migration and transformation of fibroblasts, which are the primary cells responsible for lung scarring. Anti-Angiogenic Effect: In oncology, it interferes with the tumor’s ability to develop new blood vessels, effectively limiting the supply of nutrients required for tumor expansion. 3. Administration and Dosage Management Standard Dosing: The typical recommended dose is 150mg taken twice daily, approximately 12 hours apart. Administration: Capsules must be swallowed whole with food and a full glass of water. They should not be crushed or chewed due to the bitter taste and potential for irritation. Missed Dose: If a dose is missed, the patient should skip it and take the next dose at the scheduled time; double doses should be avoided. Clinical Side Effects & Safety Monitoring Gastrointestinal Health: Diarrhea and nausea are very common; hydration and anti-diarrheal management are often necessary. Hepatotoxicity: Drug-induced liver injury is a risk; Liver Function Tests (LFTs) must be conducted before starting and periodically during treatment. Cardiovascular Risks: Monitoring for arterial thromboembolic events (such as myocardial infarction) and hypertension. Pregnancy Warning: Nintedanib can cause fetal harm; effective contraception is mandatory for female patients of reproductive potential. Why Source Nindalieva 150mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Nindalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Imalieva 400mg Tablet: Precision Tyrosine Kinase Inhibition for Chronic Hematologic Malignancies Are you searching for a reliable Imalieva 400mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of targeted kinase inhibitors. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Imalieva 400mg? Imalieva 400mg is an oral targeted therapy containing the active pharmaceutical ingredient Imatinib Mesylate. Manufactured by Allieva Pharma Pvt Ltd, this 400mg tablet is a breakthrough in the treatment of specific blood cancers and solid tumors. It belongs to the class of medications known as tyrosine kinase inhibitors (TKIs), which revolutionized oncology by targeting cancer cells at the molecular level with minimal damage to healthy cells. 1. Therapeutic Indications Chronic Myeloid Leukemia (CML): Specifically for Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast crisis phases. Acute Lymphoblastic Leukemia (ALL): Used for adult and pediatric patients with Ph+ ALL, often in combination with chemotherapy. Gastrointestinal Stromal Tumors (GIST): Indicated for the treatment of Kit (CD117) positive unresectable and/or metastatic malignant GIST. Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): Associated with PDGFR gene re-arrangements. Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL): For adult patients with specific genetic markers. 2. Mechanism of Action: Molecular Precision Enzyme Blocking: It binds to the ATP-binding site of the Bcr-Abl tyrosine kinase enzyme. This enzyme is the “on-switch“ that tells cancer cells to multiply uncontrollably. Halting Proliferation: By blocking this switch, Imalieva prevents the phosphorylation of proteins involved in signal transduction, thereby stopping the growth of the tumor. Apoptosis Induction: It encourages programmed cell death (apoptosis) in the malignant cell lines without harming the surrounding normal tissues. 3. Administration and Patient Management Standard Dosing: For most indications, the standard dose is 400mg once daily. Administration: Must be taken with a meal and a large glass of water to minimize gastrointestinal irritation. Consistency: For maximum therapeutic benefit, the medication should be taken at the same time every day. Clinical Side Effects & Safety Monitoring Fluid Retention: Monitoring for periorbital edema (swelling around eyes) or peripheral edema. Hematological Safety: Potential for Neutropenia or Thrombocytopenia; frequent CBC (Complete Blood Count) tests are mandatory. Hepatotoxicity: Regular Liver Function Tests (LFTs) are required as Imatinib can affect liver enzymes. Gastrointestinal Health: Patients may experience nausea, vomiting, or diarrhea, which can usually be managed with supportive care. Why Source Imalieva 400mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Imalieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Capelieva-DT 500mg Tablet: Innovative Dispersible Targeted Therapy for Advanced Oncology Are you searching for a reliable Capelieva-DT 500mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of innovative oral chemotherapeutic agents. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Capelieva-DT 500mg? Capelieva-DT 500mg is an advanced Dispersible Tablet (DT) formulation containing the active pharmaceutical ingredient Capecitabine. Manufactured by Allieva Pharma Pvt Ltd, this 500mg variant is specifically engineered for patients who have difficulty swallowing traditional tablets (dysphagia). It belongs to the antimetabolite class of drugs and serves as a prodrug that activates directly within tumor tissues to combat malignant growth. 1. Therapeutic Indications Colorectal Cancer: As adjuvant therapy for Dukes' C colon cancer following surgery, or as a primary treatment for metastatic colorectal cancer. Metastatic Breast Cancer: Used as monotherapy or in combination with Docetaxel for patients resistant to other chemotherapy regimens. Gastric (Stomach) & Esophageal Cancer: Integrated into first-line combination therapies for advanced gastric malignancies. Pancreatic Cancer: Often utilized in off-label specialized oncology protocols for locally advanced disease. 2. Mechanism of Action: Targeted Enzymatic Conversion Prodrug Activation: Once ingested, Capecitabine is converted through a three-step enzymatic process into 5-fluorouracil (5-FU). Tumor-Specific Targeting: The final conversion stage utilizes the enzyme thymidine phosphorylase, which is found in much higher concentrations within tumor cells compared to healthy tissue. Cytotoxic Impact: The resulting 5-FU hampers the synthesis of DNA and RNA, effectively “starving“ the cancer cells of the genetic materials needed to divide and replicate. 3. Administration and The “DT“ Advantage Dispersible Formulation: The DT (Dispersible Tablet) form is a significant advantage for geriatric or pediatric patients, as it can be easily dissolved in water to form a suspension. Timing: To ensure maximum efficacy and absorption, it must be taken within 30 minutes after finishing a meal. Cycle Management: Typically administered in a 21-day cycle (14 days of treatment followed by a 7-day rest period), or as strictly directed by an oncologist. Clinical Side Effects & Safety Monitoring Hand-Foot Syndrome: Monitoring for redness, swelling, or pain on the palms and soles of the feet. Gastrointestinal Health: Potential for severe diarrhea or dehydration; electrolyte management is critical. Hematological Safety: Regular monitoring of Complete Blood Counts (CBC) to manage risks of Neutropenia. Hepatotoxicity: Periodic liver function tests (LFTs) are recommended to ensure systemic safety. Why Source Capelieva-DT 500mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Capelieva-DT with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Capelieva 500mg Tablet: Advanced Oral Chemotherapy for Targeted Oncology CareAre you searching for a reliable Capelieva 500mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of oral chemotherapeutic agents. We maintain an agile and secure supply chain for London (UK), Washington (USA), Canberra (Australia), and South Africa, ensuring that critical oncology medications reach institutional pharmacies with 100% pharmaceutical integrity. Detailed Product Profile: What is Capelieva 500mg? Capelieva 500mg is an oral targeted chemotherapy containing the active pharmaceutical ingredient Capecitabine. Manufactured by Allieva Pharma Pvt Ltd, this 500mg tablet belongs to the category of antimetabolites. It is specifically designed to interfere with the growth and reproduction of cancer cells, serving as a cornerstone in modern oncology protocols. 1. Therapeutic Indications Colorectal Cancer: Used as a primary treatment for colon and rectal cancers, both as monotherapy and in combination regimens. Breast Cancer: Indicated for metastatic breast cancer, particularly in patients who have not responded to other chemotherapy treatments like taxanes or anthracyclines. Gastric (Stomach) Cancer: Effectively used in the treatment of advanced gastric and esophageal junction cancers. Adjuvant Therapy: Used post-surgery to prevent the recurrence of cancer in the colon after complete tumor removal. 2. Mechanism of Action: Targeted Cytotoxic Effect Prodrug Activation: Once ingested, Capecitabine is converted by enzymes into 5-fluorouracil (5-FU). Targeted Cell Death: This conversion primarily occurs within tumor tissues, where 5-FU hampers the synthesis of genetic materials (DNA), directly interfering with the growth of cancer cells. Selective Action: By targeting rapidly dividing cells, it slows down and eventually kills the malignant cells while attempting to minimize impact on healthy tissue. 3. Administration and Cycle Management Standard Dosing: Typically taken twice daily, Capelieva follows a specific cycle (often 14 days of treatment followed by a 7-day rest period). Timing: Must be taken within 30 minutes after a meal with a full glass of water. Form: Capsules must be swallowed whole; do not crush, chew, or break them Clinical Side Effects & Safety Monitoring Hand-Foot Syndrome: Redness, pain, or blisters on the palms and soles (Palmar-plantar erythrodysaesthesia). Gastrointestinal Health: Potential for diarrhea, nausea, vomiting, and mouth ulcers. Hematological Safety: Risk of increased infection due to changes in white blood cell counts. General Vitality: Loss of appetite, fatigue, and hair loss are common but manageable side effects. Why Source Capelieva 500mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva Pharma’s Capelieva with full batch-specific COA and traceability. Logistics Authority: Expert handling of complex import/export regulations for USA, UK, Australia, and South Africa. Wholesale Solutions: Competitive bulk pricing for hospital groups, specialty pharmacies, and regional distributors. Regulatory Compliance: Every shipment includes GMP certificates and comprehensive B2B documentation to ensure global standards. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383

Abiralieva 500mg Tablet: High-Potency Androgen Biosynthesis Inhibition for Global Prostate Cancer Sourcing Are you searching for a verified Abiralieva 500mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced uro-oncology medications. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that high-strength hormone-targeted therapies reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Abiralieva 500mg? Abiralieva 500mg is an oral targeted therapy containing the active pharmaceutical ingredient Abiraterone Acetate. Manufactured by Allieva, the 500mg tablet is a high-potency formulation designed to streamline the dosing regimen for patients with advanced prostate cancer. As an androgen biosynthesis inhibitor, it is engineered to shut down testosterone production at the source, effectively “starving“ the tumor cells of the fuel they need to grow. 1. Therapeutic Indications Abiralieva 500mg is clinically utilized globally for the treatment of: Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread and no longer responds to surgical or medical treatments that lower testosterone. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used as a frontline treatment in combination with androgen deprivation therapy (ADT). High-Risk Non-Metastatic Disease: In specific clinical settings, to prevent disease progression in patients at high risk of metastasis. Standard Combination: Usually prescribed with low-dose Prednisone to manage mineralocorticoid levels and ensure patient safety. 2. Mechanism of Action: The Triple-Pathway Blockade Most prostate cancer treatments only address testosterone from the testes. Abiralieva provides a more comprehensive blockade by inhibiting the enzyme CYP17: Adrenal Gland Inhibition: Stops the production of androgens from the adrenal glands. Intra-Tumoral Suppression: Blocks the ability of the prostate cancer cells themselves to produce testosterone—a common cause of therapy resistance. Testicular Blockade: Works alongside other therapies to ensure total androgen suppression. Result: By eliminating testosterone from all three sources, it slows tumor growth and significantly extends progression-free survival. 3. Administration and Dosage (500mg Advantage) Convenient Dosing: The 500mg strength allows for a reduced pill burden, typically administered as two 500mg tablets (1,000 mg total) taken once daily. Empty Stomach Requirement: Abiralieva must be taken on an empty stomach (at least 1 hour before or 2 hours after food). Food can cause unpredictable and dangerous spikes in drug absorption. Swallow Whole: Tablets must not be crushed, chewed, or broken to maintain the integrity of the medication. Clinical Side Effects & Safety Monitoring Patients on Abiralieva 500mg require regular medical supervision to manage the following potential side effects: Mineralocorticoid Excess: Can lead to high blood pressure (hypertension), fluid retention (edema), and low potassium (hypokalemia). Monthly monitoring is essential. Hepatotoxicity: Potential for elevated liver enzymes. Liver function tests (LFTs) are mandatory every two weeks for the first three months of treatment. Cardiovascular Risks: Use with caution in patients with a history of heart failure or recent myocardial infarction. General: Hot flushes, joint pain (arthralgia), muscle discomfort, and diarrhea. Why Source Abiralieva 500mg from Ernest Oncology? In 2026, global oncology procurement relies on Supply Chain Resilience and Verified Traceability. Ernest Oncology offers: Verified Authenticity: Direct sourcing of Allieva’s Abiralieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, urology networks, and regional distributors. Compliance Excellence: Every shipment is accompanied by GMP certificates and complete B2B documentation 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Abiralieva 250mg Tablet: Advanced Androgen Biosynthesis Inhibition for Global Prostate Cancer Care Are you searching for a verified Abiralieva 250mg Tablet exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced uro-oncology medications. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical hormone-targeted therapies reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Abiralieva 250mg? Abiralieva 250mg is an oral targeted therapy containing the active pharmaceutical ingredient Abiraterone Acetate. Manufactured by Allieva, this 250mg tablet belongs to a specialized class of medications known as androgen biosynthesis inhibitors. It is a fundamental treatment for advanced prostate cancer, specifically designed to halt the production of the very hormones that drive the growth of malignant prostate cells. 1. Therapeutic Indications Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread to other parts of the body and no longer responds to surgical or medical treatments that lower testosterone. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with androgen deprivation therapy (ADT) for patients with newly diagnosed metastatic disease. Combination Therapy: It is almost always prescribed in combination with low-dose Prednisone or Prednisolone to help manage potential side effects related to mineralocorticoid excess. 2. Mechanism of Action: Triple-Source Testosterone Blockade Testicular Suppression: It blocks the final steps of testosterone production in the testes. Adrenal Gland Inhibition: It prevents the adrenal glands from producing precursor hormones that can be converted into testosterone. Intra-Tumoral Blockade: Crucially, it stops the prostate tumor itself from manufacturing its own testosterone—a common cause of treatment resistance. Result: This total suppression “starves“ the cancer cells of their primary growth signal, leading to tumor shrinkage and delayed disease progression. 3. Administration and Usage Guidelines Empty Stomach Requirement: Abiralieva 250mg must be taken on an empty stomach (at least 1 hour before or 2 hours after food). Taking it with food can significantly increase absorption to dangerous levels, causing toxicity. Dosage: The standard dose is often 1,000 mg (four 250mg tablets) taken as a single daily dose.Handling: Tablets should be swallowed whole with water. Do not crush, chew, or break them. Clinical Side Effects & Safety Monitoring Mineralocorticoid Excess: Can cause high blood pressure (hypertension), fluid retention (edema), and low potassium levels (hypokalemia). This is why it is used with Prednisone. Hepatotoxicity: Potential for increased liver enzymes. Periodic liver function tests (LFTs) are mandatory during treatment. Gastrointestinal: Nausea, vomiting, and diarrhea. General: Fatigue, hot flushes, joint pain (arthralgia), and muscle discomfort. Cardiac Risks: Patients with a history of cardiovascular disease require close monitoring for irregular heartbeat or heart failure. Why Source Abiralieva 250mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Abiralieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, urology networks, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Palbolieva 125mg Capsule: Maximum Potency CDK4/6 Inhibition for Advanced HR+/HER2- Breast Cancer Care Are you searching for a verified Palbolieva 125mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted breast cancer therapies. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that high-dose cyclin-dependent kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Palbolieva 125mg? Palbolieva 125mg is an oral targeted chemotherapy medication containing the active pharmaceutical ingredient Palbociclib. Manufactured by Allieva, the 125mg strength is the standard therapeutic starting dose for most patients. It belongs to a revolutionary class of drugs called CDK4/6 inhibitors, designed to specifically block the proteins that drive the rapid division of hormone-receptor-positive breast cancer cells. 1. Therapeutic Indications HR+, HER2- Metastatic Breast Cancer: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread. Initial Endocrine-Based Therapy: Often prescribed in combination with an aromatase inhibitor (like Letrozole or Anastrozole) as a first-line treatment for postmenopausal women or men. Progressive Disease Therapy: Used in combination with Fulvestrant for patients whose cancer has progressed after prior endocrine therapy. 2. Mechanism of Action: Arresting the Malignant Cell Cycle Kinase Blockade: It selectively inhibits Cyclin-Dependent Kinases 4 and 6 (CDK4/6). In many breast cancers, these kinases are overactive, pushing cells to divide uncontrollably. G1-Phase Arrest: By blocking these enzymes, Palbolieva prevents the cancer cell from moving from the growth phase (G1) to the DNA replication phase (S). Halting Proliferation: This results in “cell cycle arrest,“ which stabilizes the tumor, reduces its size, and significantly extends progression-free survival (PFS). 3. Administration and Dosing Schedule Standard Regimen: Typically administered in a 28-day cycle—one 125mg capsule daily for 21 consecutive days, followed by 7 days of rest. Bioavailability: Palbolieva 125mg should be taken with food at approximately the same time each day to ensure the drug is absorbed correctly by the body. Handling: Capsules must be swallowed whole; they should not be opened, crushed, or chewed. Clinical Side Effects & Safety Monitoring Neutropenia: A significant decrease in white blood cells (neutrophils) is common. Regular complete blood counts (CBC) are mandatory before starting each cycle. Infection Risk: Due to lower blood counts, patients must monitor for signs of fever or chills. Gastrointestinal: Nausea, diarrhea, and mouth sores (stomatitis) are frequently observed. General Fatigue: Significant tiredness or lack of energy is a known clinical side effect. Dermatological: Potential for thinning of the hair (alopecia) or dry skin. Drug Interactions: Avoid grapefruit products and certain herbal supplements like St. John’s Wort, as they can alter the drug's efficacy and toxicity levels. Why Source Palbolieva 125mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Palbolieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Bulk Supply Solutions: Competitive wholesale pricing for hospital groups, specialty oncology pharmacies, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

Palbolieva 100mg Capsule: Breakthrough CDK4/6 Inhibition for Advanced HR+/HER2- Breast Cancer Care Are you searching for a verified Palbolieva 100mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted breast cancer therapies. We provide a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical cyclin-dependent kinase inhibitors reach oncology centers with 100% pharmaceutical integrity. Detailed Product Profile: What is Palbolieva 100mg? Palbolieva 100mg is an oral targeted therapy containing the active pharmaceutical ingredient Palbociclib. Manufactured by Allieva, this 100mg capsule is a potent CDK4/6 inhibitor. It has revolutionized the treatment landscape for hormone-driven breast cancers by specifically targeting the machinery that allows cancer cells to divide and multiply. 1. Therapeutic Indications HR+, HER2- Advanced Breast Cancer: For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic). First-Line Combination Therapy: Frequently used in combination with an aromatase inhibitor (such as Letrozole) as the initial endocrine-based therapy for postmenopausal women. Second-Line Combination Therapy: Prescribed in combination with Fulvestrant for patients whose disease has progressed following prior endocrine therapy. 2. Mechanism of Action: Arresting the Cell Cycle Enzyme Inhibition: It targets two specific proteins called cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These proteins are often overactive in breast cancer cells. Phase Arrest: By blocking these kinases, Palbolieva prevents the cancer cell from progressing from the G1 phase to the S phase of the cell cycle. Proliferation Stop: This effectively locks the cancer cell in a non-dividing state, significantly slowing down tumor growth and delaying disease progression. 3. Administration and Dosing Cycle Management: Typically taken in a 21-day on, 7-day off cycle. This rest period allows the body's healthy cells, particularly blood cells, to recover. Timing: Palbolieva 100mg should be taken with food at approximately the same time each day to ensure optimal absorption. Consistency: Adherence to the prescribed cycle is vital for maintaining the “cell cycle arrest“ required to shrink or stabilize tumors. Clinical Side Effects & Safety Monitoring Neutropenia: The most common side effect is a decrease in white blood cells (Neutropenia). Regular complete blood counts (CBC) are mandatory before each cycle to monitor infection risk. Infections: Due to lowered blood counts, patients may be more susceptible to infections. Report fever or chills immediately. Gastrointestinal: Nausea, diarrhea, and stomatitis (mouth sores) are frequently observed clinical side effects. Dermatological: Potential for thinning of the hair (alopecia) or skin rashes. Fatigue & Dizziness: Significant tiredness (asthenia) or dizziness may occur, impacting daily activities. Precautions: Avoid grapefruit and grapefruit juice, as they can interfere with how the body processes the medication, leading to increased toxicity. Why Source Palbolieva 100mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Palbolieva with full batch-specific traceability and COA. Logistics Authority: Expert handling of complex import regulations for London (UK), the USA, Australia, and South Africa. Wholesale Fulfillment: Competitive bulk pricing and steady inventory for hospital groups, breast cancer specialty clinics, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp